Testing B1962 for Advanced Solid Tumors After Standard Treatment
Part of Cancer, Digestive system, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called B1962 for people with advanced solid tumors that have not responded to or can no longer be treated with standard therapies. It is for specific cancers like ovarian, breast, lung, or liver cancer, and you must not have previously taken certain immune-based or anti-angiogenic treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have one of these advanced cancers: ovarian, triple-negative breast, cervical, small-cell lung, bile duct, liver, colorectal, or non-squamous non-small cell lung cancer that has continued to grow despite standard treatment (like chemotherapy) or you couldn't tolerate that treatment.
- You must have tried no more than 4 previous cancer treatments.
- You cannot have already taken a PD-1 or PD-L1 checkpoint inhibitor medicine (like Keytruda or Tecentriq) or a VEGF/VEGFR inhibitor (like Avastin or Cyramza).
- Your cancer must have at least one tumor that can be measured on a CT or MRI scan.
- You must be generally healthy enough to get around (ECOG score 0-1) and have adequate organ function (kidneys, liver, blood cells).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This Phase 1/2 study tests BL-B01D1 in people with recurrent or metastatic gynecologic cancers (such as ovarian, uterine, or cervical cancer) when standard treatments have failed or aren’t options. It focuses on how well the drug works and whether it can be given safely.
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
This trial tests a new injection called B1962 for people with advanced colorectal cancer that has spread or cannot be removed by surgery, and who have already tried standard treatments. The goal is to see if B1962 can help shrink tumors or slow the disease.
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.